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B cell CLL/lymphoma 11A (BCL11A) is a transcription
factor and regulator of hemoglobin switching that
has emerged as a promising therapeutic target for
sickle cell disease and thalassemia. In the hemato-
poietic system, BCL11A is required for B lympho-
poiesis, yet its role in other hematopoietic cells,
especially hematopoietic stem cells (HSCs) remains
elusive. The extensive expression of BCL11A in
hematopoiesis implicates context-dependent roles,
highlighting the importance of fully characterizing
its function as part of ongoing efforts for stem cell
therapy and regenerativemedicine. Here, we demon-
strate that BCL11A is indispensable for normal HSC
function. Bcl11a deficiency results in HSC defects,
typically observed in the aging hematopoietic sys-
tem. We find that downregulation of cyclin-depen-
dent kinase 6 (Cdk6), and the ensuing cell-cycle
delay, correlate with HSC dysfunction. Our studies
define a mechanism for BCL11A in regulation of
HSC function and have important implications for
the design of therapeutic approaches to targeting
BCL11A.
INTRODUCTION
Hematopoietic development in mammals emerges in sequential
waves that include primitive anddefinitivewaves. Primitive hema-
topoiesis gives rise to transient macrophages, megakaryocytes,
and large nucleated erythroid progenitors characterized by the
production of embryonic globins. The definitive wave of hemato-
poiesis gives rise to hematopoietic stem cells (HSCs), defined by
their ability to self-renew to sustain theHSCpopulation and differ-
entiate to regenerate the entire hematopoietic system from the
embryo into adult life (Palis, 2014; Seita and Weissman, 2010).Cell Repo
This is an open access article under the CC BY-NB cell CLL/lymphoma 11A (BCL11A) is a C2H2 zinc-finger
transcription factor expressed in the hematopoietic system
and brain (Liu et al., 2003). Bcl11a-null mice are perinatal lethal
and have impaired lymphopoiesis, particularly in the B cell line-
age (Liu et al., 2003; Sankaran et al., 2009). During embryonic
development, the expression of BCL11A and other transcrip-
tional regulators, such as SOX6 and MYB, coincides with defin-
itive hematopoiesis in both human and mouse (Palis, 2014;
Sankaran et al., 2009; Xu et al., 2010), although a more recent
report suggests that BCL11A may be expressed even earlier,
at the pre-HSC stage (Zhou et al., 2016).
Genome-wide association studies (GWASs) have identified
BCL11A as a major fetal hemoglobin (HbF)-associated locus
(Lettre et al., 2008; Menzel et al., 2007; Uda et al., 2008). Subse-
quent studies demonstrated that BCL11A is expressed in adult
definitive erythroid cells and acts as a transcriptional repressor
of human fetal and mouse embryonic b-like globin genes (Bauer
et al., 2013; Sankaran et al., 2008, 2009; Xu et al., 2011). Given its
critical role in hemoglobin switching, BCL11A has emerged as a
promising therapeutic target for the major b-globin disorders.
However, its essential role in normal B lymphopoiesis under-
scores the importance of delineating the full extent of BCL11A’s
function in other cellular contexts within the hematopoietic sys-
tem to address target-related toxicities in therapy. Bcl11a is ex-
pressed in multiple hematopoietic lineages besides B lymphoid
and erythroid cells, including bone marrow (BM) progenitor cells
and HSCs (Yu et al., 2012). Furthermore, its temporal expression
in embryonic development coincides with the emergence of
definitive hematopoiesis, warranting exploration of its role in
establishing the identity and function of definitive HSCs. This
is especially relevant considering current efforts to generate
bona fide HSCs through directed differentiation of pluripotent
embryonic stem cells (ESCs) and reprogramming of induced
pluripotent stem cells (iPSCs) for disease-modeling and clinical
applications. Although it is possible to make cells that pheno-
typically resemble definitive HSCs, it remains challenging
to generate transplantable long-term definitive HSCs. The
limited success of current strategies is partly because of therts 16, 3181–3194, September 20, 2016 ª 2016 The Authors. 3181
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
embryonic-like nature of the ESC- or iPSC-derived hematopoi-
etic cells that are developmentally restricted from becoming
competent definitive HSCs. Hence, elucidating the role of tran-
scription factors such as BCL11A in definitive hematopoiesis
may provide insights into developing improved strategies to
overcome these obstacles (Daniel et al., 2016).
Here, we use an inducible, conditional Bcl11a knockout (KO)
mouse strain (Ippolito et al., 2014; Sankaran et al., 2009) to
examine the role of Bcl11a in definitive hematopoiesis. We
demonstrate that Bcl11a is indispensable for normal HSC func-
tion. Bcl11a-deficient HSCs exhibit cell-cycle defects resem-
bling a premature aging phenotype that is associated with
impaired HSC multilineage differentiation and self-renewal. Our
studies suggest a mechanism for BCL11A in regulating definitive
hematopoiesis and have important implications for the thera-
peutic targeting of BCL11A.
RESULTS
Bcl11a Is Required for Stem and Progenitor Cells in
Embryonic Development
Bcl11a is widely expressed in the definitive hematopoietic sys-
tem, including HSCs and downstream myeloid and lymphoid
progenitors (Figure S1A) (Yu et al., 2012). To evaluate the role
of BCL11A in steady-state hematopoiesis, we used a conditional
Bcl11amouse strain (Ippolito et al., 2014; Sankaran et al., 2009),
Bcl11a floxed (Bcl11afl/fl), crossedwith theGata1-Cre transgenic
mice to achieve germline deletion (Figure S1B) (Jasinski et al.,
2001). BCL11A is a critical repressor of human HbF and mouse
embryonic b-like globin genes (εy and bh1) (Sankaran et al.,
2009). Consistently, we observed a marked increase in mouse
εy- and bh1-globin mRNA in embryonic day (E) 18.5Bcl11a-defi-
cient fetal liver cells (Figures S1C and S1D).
Similar to the conventional Bcl11a KO mouse, Bcl11afl/fl 3
Gata1-Cremicewereperinatal lethal (Sankaranetal., 2009).B lym-
phopoiesis was significantly impaired in Bcl11a-null E18.5 fetal
livers and spleens (Figures 1A and 1B; Figures S1E and S1F). In
parallel, there was a marked decrease in the frequency of
lymphoid-primed multipotent progenitor (LMPP; LinSca-1+c-
Kit+(LSK)Flt3+CD150) and common lymphoid progenitor (CLP;
LinFlt3+IL-7Ra+c-KitlowSca-1low), both considered precursors of
B cells, in Bcl11a-null E14.5 and E17.5 fetal livers (Figure 1C; Fig-
uresS1GandS1H).AlthoughBcl11adeficiencyminimally affected
maturemyeloid cells (Liu et al., 2003), analysis of the myeloid pro-
genitors, granulocyte-monocyte progenitor (GMP; LinSca-1c-
Kit+CD41CD150CD16/32+) and megakaryocyte progenitor
(MkP; LinSca-1c-Kit+CD150+CD41+), demonstrated a modest
decrease in E17.5 Bcl11a-null embryos (Figure 1D; Figure S1I).
Moreover, phenotypic HSCs were reduced by 3.8-fold and 1.9-
fold in Bcl11a-null E14.5 and E17.5 embryos, respectively (Fig-
ure 1E; Figure S1J). These refined analyses demonstrate that
Bcl11a is required not only for B lymphopoiesis but also for
HSCs or progenitor cells during mouse embryonic development.
Acute Loss of Bcl11a in Steady-State Hematopoiesis
Impairs Lymphopoiesis
Given the perinatal lethality following germline deletion of
Bcl11a, we then crossed the Bcl11afl/fl strain to the interferon-3182 Cell Reports 16, 3181–3194, September 20, 2016inducible myxovirus resistance 1 (Mx1)-Cre mouse strain (K€uhn
et al., 1995) to evaluate the role of BCL11A in postnatal hemato-
poiesis. We obtained non-deleted (wild-type, WT; Bcl11afl/fl 3
Mx1-Cre), heterozygously deleted (Het; Bcl11afl/wt 3 Mx1-
Cre+), and homozygously deleted (KO; Bcl11afl/fl 3 Mx1-Cre+)
animals by administration of polyinosinic:polycytidylic acid, or
p(I:C) (Figure 2A). Both Het and KO mice were viable following
p(I:C) treatment, and the BCL11A protein was ablated from the
BM of Bcl11a KOmice (Figure S2A). Although the Mx1 promoter
is active in BM stromal cells, there was no evidence of BCL11A
expression in the BMstromal cell compartment (Figures S2B and
S2C). To facilitate the assessment and tracking of deleted cells,
Bcl11afl/fl 3 Mx1-Cre mice were also crossed to the Rosa26-
stop-EYFP (R26-eYFP) reporter strain (Srinivas et al., 2001).
Upon p(I:C)-induced gene deletion, B cells (B220+CD19+) were
the only blood lineage negatively affected, while the frequency
of T cells (CD3ε+Thy1.2+) remained largely unchanged and the
frequency of myeloid cells (Mac-1+Gr-1+) was increased by
10 weeks in the peripheral blood (Figure 2B). R26-eYFP reporter
expression showed high deletion efficiency in all lineages, which
was confirmed by mRNA expression of Bcl11a and embryonic
b-like globin genes (Figures S2D–S2G). Consistently, among
the mature blood lineages in the BM, only B cells were nega-
tively affected by Bcl11a loss (Figure 2C; Figure S3A). Further-
more, ProB cells (B220+CD43+IgMCD19+CD24lowCD93+) and
PreB cells (B220+CD43+IgMCD19+CD24hiCD93+) were absent
and PreProB cells (B220+CD43+IgMCD19CD24CD93+) were
markedly reduced in Bcl11a KO BM, suggesting a block in B
cell development at the PreProB and ProB cell stages, consistent
with a previous report (Yu et al., 2012) (Figure 2D; FiguresS3Band
S3C). Although both mature B cells and B cell progenitors were
present in theHet animals, theywere decreased to levels interme-
diate of WT and KO mice (Figures 2C and 2D). The frequency of
myeloid cells (Mac-1+Gr-1+) and T cells (CD3ε+) was increased
in the Bcl11a-null BM, whereas erythroid cells (Ter119+CD71+)
remained unaltered (Figure 2C; Figure S3A). However, early
thymic progenitors (ETPs; LinCD4CD8ac-Kit+CD25) were
significantly decreased in Bcl11a-deficient thymus, whereas
double-negative (DN) 2 (LinCD4CD8ac-Kit+CD25+), DN3
(LinCD4CD8ac-KitCD25+), and DN4 (LinCD4CD8ac-
KitCD25) T cells were not significantly affected (Figure S3D).
These findings suggest that Bcl11a is indispensable for both B
and early T cell progenitors.
To assess whetherBcl11a is required upstream in the hemato-
poietic hierarchy, we next analyzed the primitive BM progenitor
compartment. Consistent with a decrease in the B cell lineage
and ETPs, LMPPs (LSKFlt3+CD150) were nearly absent in
Bcl11a KO mice, whereas the myeloid progenitor compartment
including GMPs (LinSca-1c-Kit+CD41CD150CD16/32+)
and MkPs (LinSca-1c-Kit+CD150+CD41+) (Figure 2E; Fig-
ures S3E and S3F) was modestly increased. There was an
increase in the frequency and number of phenotypic HSCs
(LSKCD48Flt3CD150+) in Bcl11a KO mice (Figure 2F; Fig-
ure S3G), which was not due to inefficient gene deletion (Figures
S3H and S3I). These data demonstrate that acute loss of Bcl11a
in the BM resulted in impaired normal lymphopoiesis, a parallel
increase in the myeloid compartment, and alterations in the
frequency of steady-state HSCs.
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Figure 1. Decreases in HSCs and Lymphoid Progenitors in Bcl11a-Deficient Embryos
(A) PreProB cell and ProB cell/PreB cell (ProB/PreB) frequency in E18.5 fetal liver of Bcl11afl/D 3 Gata1-Cre embryos.
(B) ProB/PreB and IgM+ B cell frequency in E18.5 fetal spleen of Bcl11afl/D 3 Gata1-Cre embryos.
(C) LMPP and CLP frequency in E14.5 and E17.5 fetal liver of Bcl11afl/D 3 Gata1-Cre embryos.
(D) GMP and MkP frequency in E14.5 and E17.5 fetal liver of Bcl11afl/D 3 Gata1-Cre embryos.
(E) HSC (LSKCD48Flt3CD150+) frequency in E14.5 and E17.5 fetal liver of Bcl11afl/D 3 Gata1-Cre embryos.
Error bars represent mean ± SD. In (A) and (B), n = 5–6 WT, 4–8 Het, and 2–4 KO from E18.5 embryos. In (C)–(E), n = 2 WT, 9 Het, and 10 KO from E14.5 embryos
and n = 2 WT, 2 Het, and 4 KO from E17.5 embryos. *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S1.Bcl11a Is Required for Normal HSC Function
Given the increased HSC frequency inBcl11a-deficient mice, we
next performed a non-competitive transplantation using 13 106
whole BM cells from Bcl11a KOmice to functionally evaluate the
HSCactivity. The donor contribution, measured as the frequency
of R26-eYFP+ cells in peripheral blood, rapidly declined after
transplantation. Donor chimerism (R26-eYFP+) in the BM was
barely detectable 13 weeks post-transplantation (Figure S4A).
To assess whether the impaired repopulation capacity of the
Bcl11a KO BM cells was due to an intrinsic effect, we purified
phenotypic HSCs (LSKCD48Flt3CD150+) from Bcl11a WT,
Het, and KO and performed a competitive transplantation. To
ascertain that Bcl11a deficiency did not impede homing of the
transplanted cells to the BM niche, gene deletion was inducedonly after confirming reconstitution of the injected cells (Fig-
ures 3A and 3B). Following Bcl11a deletion, donor contribution
(CD45.2+) in the peripheral blood drastically decreased in the
KO transplanted animals (Figure 3B). All donor-derived blood
lineages (CD45.2+) in the peripheral blood, including B, T, and
myeloid cells were markedly reduced in both Het and KO trans-
planted mice (Figure S4B). The myeloid predominance noted in
steady-state hematopoiesis wasmore pronounced (Figure S4C).
Moreover, Bcl11a Het HSCs reconstituted myeloid cells to inter-
mediate levels compared to WT and KO HSCs but were not as
efficient in contributing to the lymphoid lineages, in particular B
cells (Figure S4B). Consistently, analysis of the BM of trans-
planted mice at 18 weeks demonstrated that repopulation from
Bcl11a KO cells to mature blood lineages (Figures 3C and 3D)Cell Reports 16, 3181–3194, September 20, 2016 3183
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Figure 2. Acute Deletion of Bcl11a in Steady-State Hematopoiesis Results in Loss of Lymphoid Progenitors and B Cells
(A) Experimental design for characterization of the hematopoietic system following acute deletion of Bcl11a.
(B) Frequency of peripheral blood B, T, and myeloid cells 3 and 10 weeks after Bcl11a gene deletion.
(C) Frequency of BM myeloid (M), erythroid (E), B, and T cells 13 weeks after Bcl11a gene deletion.
(D) Frequency of BM B cell progenitors 13 weeks after Bcl11a gene deletion.
(E) Frequency of BM GMPs, MkPs, and LMPPs 13 weeks after Bcl11a gene deletion.
(F) Frequency of BM HSCs 13 weeks after Bcl11a gene deletion (right) and representative FACS profiles (left). Mean frequencies of total HSCs from kit-enriched
BM are shown in the FACS plots.
Error bars represent mean ± SD. In (B), n = 8 WT, 5 Het, and 8 KO. In (C)–(F), n = 7 WT, 4 Het, and 7 KO. *p < 0.05; **p < 0.01; ***p < 0.001. See also Fig-
ures S2 and S3.
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Figure 3. HSCs from Bcl11a-Deficient Mice Have Impaired Repopulation Ability
(A) Experimental design to evaluate HSC activity from Bcl11a-deficient mice.
(B) Donor chimerism in peripheral blood following transplantation of HSCs from Bcl11a WT, Het, and KO mice before and after Bcl11a gene deletion.
(C) Frequency of donor-derived BM myeloid (M), B, natural killer (NK), and T cells 18 weeks after Bcl11a gene deletion.
(D) Frequency of donor-derived BM B cell progenitors 18 weeks after Bcl11a gene deletion.
(E) Frequency of donor-derived BM GMPs, MkPs, and LMPPs 18 weeks after Bcl11a gene deletion.
(F) Frequency of donor-derived BMHSCs 18weeks afterBcl11a gene deletion (right) and representative FACS profiles (left). Mean frequencies of total HSCs from
kit-enriched BM are shown in the FACS plots.
Error bars represent mean ± SD. In (B), n = 7 WT, 8 Het, and 7–8 KO. In (C)–(F), n = 6 WT, 7 Het, and 6 KO. *p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S4.
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Figure 4. Bcl11a Deficiency Results in Impaired HSC Self-Renewal Capacity
(A) Donor chimerism in peripheral blood following secondary transplantation of Bcl11a WT, Het, and KO HSCs isolated from primary transplanted mice.
(B) Donor-derived B, T, and myeloid cells in peripheral blood from (A).
(C) Donor chimerism in BM 21 weeks after secondary transplantation of Bcl11a WT, Het, and KO HSCs.
(D) Frequency of donor-derived BM myeloid (M), B, natural killer (NK), and T cells 21 weeks after secondary transplantation.
(E) Frequency of donor-derived BM B cell progenitors 21 weeks after secondary transplantation.
(F) Frequency of donor-derived BM GMPs, MkPs, and LMPPs 21 weeks after secondary transplantation.
(G) Frequency of donor-derivedBMHSCs 21weeks after secondary transplantation (right) and representative FACSprofiles (left). Mean frequencies of total HSCs
from kit-enriched BM are shown in the FACS plots.
Data and error bars represent mean ± SD. In (A)–(G), n = 9 WT, 9 Het, and 7 KO. *p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S5.and progenitor populations (GMP, MkP, and LMPP) (Figure 3E)
was severely impaired. The myeloid lineage appeared to be
the least affected.
HSCs from both Bcl11a Het and KOmice failed to reconstitute
HSCs to thesame level asWTcontrols (Figure3F;FigureS4D). The
reconstitution ability ofBcl11aKOHSCs did not improve even un-
der lower proliferation pressure by transplantation into sublethally
irradiated recipients (Figure S4E). Upon transplantation of equal
numbers of Bcl11a WT and KO HSCs into the same irradiated
recipient, Bcl11a-deficient HSCs were rapidly outcompeted by
WT cells (Figure S4F). Even five times more Bcl11a KO HSCs
were not sufficient to maintain long-term repopulation (Fig-
ureS4G).Collectively, these resultsdemonstrate thatBcl11a-defi-
cient HSCs are at a competitive disadvantage and Bcl11a is
indispensable for normal HSC repopulation capacity.
The inability of Bcl11a-deficient cells to reconstitute HSCs
indicates that there might be a self-renewal defect, in addition3186 Cell Reports 16, 3181–3194, September 20, 2016to impaired repopulation. Thus, we purified donor-derived
phenotypic HSCs (LSKCD48Flt3CD150+CD45.2+ WT or
LSKCD48Flt3CD150+CD45.2+eYFP+ Het and KO) from pri-
mary transplanted recipients and performed secondary trans-
plantation. Consistent with a self-renewal defect, Bcl11a-defi-
cient HSCs failed to reconstitute secondary transplanted
animals (Figure 4A). Although Bcl11a Het HSCs were successful
in reconstituting secondary recipients, albeit to a lower degree
compared to WT HSCs, they were ultimately unable to produce
B and T lymphoid cells (Figure 4B; Figure S5).
Analysis of the BM confirmed that Bcl11a KO HSCs were un-
able to repopulate the secondary recipients, including reconsti-
tuting HSCs (Figures 4C–4G). Bcl11a Het HSCs demonstrated
only modest BM reconstitution (Figure 4C) and almost exclu-
sively produced myeloid cells but failed to contribute to the
lymphoid lineages (Figures 4D and 4E). Moreover, the myeloid
progenitors GMP and MkP were present at a lower frequency
in Bcl11a Het transplants compared to WT controls (Figure 4F).
Unexpectedly, Bcl11a Het HSCs partially reconstituted LMPPs,
albeit at a low frequency, despite absence of downstream
lymphoid cells (Figure 4F). Analysis of the Bcl11a Het HSCs sug-
gests that the observed lymphoid defect is exacerbated with
serial transplantation. In summary, these findings demonstrate
that Bcl11a is required not only for multilineage repopulation
but also for HSC self-renewal.
Gene Expression Profiling of Bcl11a-Deficient HSCs
Shows Cell-Cycle Defects
To determine the molecular basis of the observed defects
in Bcl11a-deficient HSCs, we performed global gene expression
analysis. Comparison of transcriptomic profiles between Bcl11a
WT and Bcl11a KO HSCs identified 620 genes to be differen-
tially expressed (419 upregulated and 201 downregulated; fold
changeR 2, p < 0.01) (Figure 5A). To identify candidate cellular
processes affected by Bcl11a loss, we performed pathway ana-
lyses (see Experimental Procedures). Genes significantly upre-
gulated in Bcl11a KO relative to WT HSCs were highly enriched
in pathways involved in development, immune response, and
cell adhesion processes (Figure 5B; Table S1). In contrast, genes
downregulated in Bcl11a KO HSCs reflected pathways required
for the cell cycle, apoptosis and survival, and DNA damage
repair (Figure 5C; Table S2).
HSCs are normally quiescent and re-enter the cell cycle in
response to various stresses (Pietras et al., 2011). Given the
increased HSC frequency but impaired HSC multilineage differ-
entiation and self-renewal in Bcl11a-null animals, we hypothe-
sized that these defects are due to defects in the cell cycle.
We identified the cyclin-dependent kinase 6 (Cdk6) gene as
being among the top 50 genes that were significantly downregu-
lated in Bcl11a KO HSCs compared to the WT controls (Fig-
ure S6). qRT-PCR analysis validated the downregulation of
Cdk6 in Bcl11a KO HSCs (p value = 0.03) (Figure 5D). CDK6 pro-
tein is expressed in the cell-cycle stage gap (G) 1 and plays an
important role in G1 cell-cycle progression (Laurenti et al.,
2015). Because the cell cycle is a highly controlled process regu-
lated by stage-specific regulators, we also examined the expres-
sion of common cell-cycle regulators (Moore, 2013; Passegue´
et al., 2005). In addition to Cdk6 (Figure 5D), we found significant
decreases in expression of the cell-cycle promoting genes cyclin
A2 (Ccna2) and cyclin B2 (Ccnb2), active in the synthesis (S) and
mitosis (M) stages of the cell cycle, respectively, in Bcl11a KO
HSCs (Figure 5E). In contrast, expression of the cell-cycle inhib-
itors p16, p21, p27, and p57 was comparable between WT and
KOgroups (Figure 5F). In addition to its role in cell-cycle progres-
sion, CDK6 is involved in regulating quiescence exit in human
HSCs (Laurenti et al., 2015). To further explore whether
decreased Cdk6 expression may affect the quiescence status
of Bcl11a KOHSCs, we performed gene set enrichment analysis
(GSEA) (Subramanian et al., 2005). Compared to the WT control,
Bcl11a KO HSCs were significantly enriched in two independent
quiescence signature gene sets (Figure 5G) (Oki et al., 2014;
Venezia et al., 2004), indicating that Bcl11a KO HSCs are more
quiescent. Collectively, these findings suggest that Bcl11a defi-
ciency in steady-state hematopoiesis alters cell-cycle progres-
sion, resulting in increased quiescence in HSCs.Bcl11a-Deficient HSCs Have Delayed Cell-Cycle
Kinetics
Given the decreased expression of several cell-cycle regulators
inBcl11aKOHSCs, we next determined the functional impact on
the cell-cycle process. In contrast to the gene expression anal-
ysis, all cell-cycle stages were comparable between Bcl11a
WT and Bcl11a KO groups (Figure 6A). To further distinguish be-
tween cells in G0 and G1 cell-cycle stages, we measured the
expression of the cell proliferation marker Ki-67 in HSCs. Cells
lacking Ki-67 protein are exclusively in the quiescent G0 stage.
Similarly, there was no significant difference between Bcl11a
WT and Bcl11a KO groups (Figure 6B). Because the S-phase
regulator Ccna2 was significantly downregulated in Bcl11a-defi-
cient HSCs (Figure 5E), we next examined the frequency of
proliferating HSCs in vivo by measuring bromodeoxyuridine
(BrdU) incorporation. Consistent with the cell-cycle analysis,
the frequencies of proliferating cells from Bcl11a KO and WT
mice were comparable at all time points (Figure 6C).
The lack of functional defects in the cell cycle following acute
deletion of Bcl11a was somewhat expected, given that the
impairment in HSC function was not evident until cells had
experienced proliferation pressure, such as in transplantation.
Consequently, we transplanted purified HSCs and analyzed
the cell-cycle status following Bcl11a gene deletion. The fre-
quency of KO HSCs in G0/G1 was significantly increased, and
that of cells in G2/M was markedly decreased (Figure 6D). How-
ever, Ki-67 staining analysis revealed a significantly lower fre-
quency of KO HSCs in G0 and a higher frequency of cells in
G1 (Figure 6E). Given that no cell-cycle stages other than G1
had increased frequency of KO HSCs, we hypothesized that
the Bcl11a-deficient HSCs are arrested or delayed in G1 due
to decreased Cdk6 expression. To test this, we purified HSCs
and cultured single cells in vitro to assess their cell division
(Figure 6F). After 24 hr, most single HSCs had gone through
only one cell division or none. Nearly twice as many WT single
HSCs (40%) had already gone through one cell division
compared to KO HSCs (21%), whereas most KO cells (69%)
had still not yet divided compared to WT control cells (54%).
At 48 hr, most WT cells (67%) had divided more than once,
compared to only 44% of the Bcl11a KO HSCs (p value =
0.04). In contrast, significantly more Bcl11a KO cells (44%)
had still only gone through one cell division compared to WT
HSCs (21%) (p value = 0.04). These findings strongly suggest
that Bcl11a-deficient HSCs have a delayed cell cycle. Specif-
ically, Bcl11a-deficient HSCs divide more slowly than WT
HSCs, despite being recruited into the cell cycle to a higher de-
gree (Figures 6D–6F). To validate these results, we used an
alternative approach to evaluate cell-cycle kinetics. Purified
HSCs were incubated with CellTrace Far Red, a cell trace dye
that dilutes with every cell division. Consistent with previous
findings, Bcl11a KO HSCs went through significantly fewer cell
divisions compared to WT HSCs (Figure 6G).
It is conceivable that a delay in cell-cycle kinetics would result
in a longer duration in the cell cycle and ultimately to a reduction
in the total cell number. To test this hypothesis, we cultured
purified single HSCs in vitro and measured their cellular expan-
sion. After 10 days of culture, WT control HSCs had expanded
on average 3,000-fold compared to only 1,900-fold from singleCell Reports 16, 3181–3194, September 20, 2016 3187
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Figure 5. Bcl11a-Deficient HSCs Have Downregulated Cdk6 Expression and a Quiescence Signature
(A) Heatmap representation of differentially regulated genes (R2-fold; p < 0.01) between Bcl11aWT and Bcl11a KO HSCs ranked according to log-fold change.
(B) Enriched pathways of genes upregulated in Bcl11a-deficient HSCs.
(C) Enriched pathways of genes downregulated in Bcl11a-deficient HSCs.
(D) Relative mRNA expression of Bcl11a and Cdk6 in sorted Bcl11a WT and KO HSCs.
(E) Relative mRNA expression of typical cell-cycle promoting genes in sorted Bcl11a WT and KO HSCs.
(legend continued on next page)
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Figure 6. Bcl11a-Deficient HSCs Have Delayed Cell-Cycle Kinetics
(A) Cell-cycle analysis by DAPI staining of Bcl11a WT and KO HSCs (left) and cell-cycle profiles (right) 7 weeks post-p(I:C). n = 4 WT and 6 KO.
(B) Cell-cycle analysis by Ki-67 andDAPI staining showing frequency of HSCs inG0 andG1 (left) and representative FACS profiles (right) 7 weeks post-p(I:C). n = 4
WT and 6 KO.
(C) Frequency of Bcl11a WT and KO HSCs with BrdU incorporation 12, 24, and 60 hr after BrdU injection in vivo. n = 3–4 WT and 3 KO.
(D) Cell-cycle analysis by DAPI staining (left) and cell-cycle profiles (right) following transplantation of Bcl11aWT and KO HSCs 4–7 weeks post-p(I:C). n = 5 WT
and 4 KO.
(E) Cell-cycle analysis by Ki-67 and DAPI staining showing frequency of HSCs in G0 and G1 (left) and the representative FACS profiles (right) following trans-
plantation of Bcl11a WT and KO HSCs 4–7 weeks post-p(I:C). n = 9 WT and 8 KO.
(F) Cell division analysis 24 and 48 hr after plating of clonal HSCs from Bcl11aWT and KO HSCs. n = 120 WT and 99 KO (24 hr) and 152 WT and 125 KO (48 hr).
(G) Flow cytometry analysis of cell division kinetics 6 days after plating HSCs from Bcl11a WT and KO HSCs. Data are from two independent experiments.
(H) Quantification of cell expansion from cultured single HSCs at day 10. n = 153 WT and 98 KO.
(I) Frequency of annexin V+ apoptotic HSCs in Bcl11a WT and KO mice. n = 7 WT and 6 KO.
Data and error bars represent mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001.Bcl11a KO HSCs (Figure 6H). Moreover, the frequency of an-
nexin V+ cells was comparable in Bcl11aWT and KOHSCs, sug-
gesting that decreased cellular output in Bcl11a KO HSCs is not
due to increased cell death (Figure 6I).
In summary, deleting Bcl11a in steady-state hematopoiesis
did not significantly affect the cell-cycle process. However, dur-(F) Relative mRNA expression of typical cell-cycle inhibitor genes in sorted Bcl11
(G) GSEA of two quiescence gene signatures in Bcl11a WT and KO HSCs.
In (A)–(C) and (G), n = 3/genotype. In (D)–(F), n = 4–7/genotype. Data in (D)–(F) rep
Tables S1 and S2.ing regeneration stress, such as after transplantation, more
Bcl11a-deficient HSCs are recruited into the cell cycle but
become delayed in G1, most likely due to decreased Cdk6
expression. The prolonged cell-cycle transit results in slower
cell-cycle kinetics compared to WT control cells and ultimately
leads to a reduced cellular output.a WT and KO HSCs.
resent mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S6 and
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Bcl11a-Deficient HSCs Resemble Aged HSCs
Physiological aging of the hematopoietic system is associated
with changes in HSCs (Geiger et al., 2013; Rossi et al., 2008).
These changes include increased HSC numbers but poorer re-
population ability, a decrease in B and T lymphoid development,
myeloid lineage skewing, and cell-cycle alterations. Given the
similarity in phenotypes observed between Bcl11a KO HSCs
and aged HSCs, we explored the resemblance in greater detail.
We first performed GSEA using two published aging HSC signa-
ture gene sets (Flach et al., 2014; Sun et al., 2014a) and found
that Bcl11a KO HSCs significantly enriched for both signatures
(Figure 7A). Because the expression of several cell-cycle regula-
tors was decreased in Bcl11a KO HSCs (Figure 5E), we next
examined the expression of Bcl11a and the cell-cycle genes
in HSCs isolated from 2-month-old young mice and 15- to 17-
month-old mice. Although the expression of Bcl11awas compa-
rable, there was a significant decrease in Cdk6 expression in
the older mice (Figure 7B). In parallel, there were significant de-
creases in the expression of Ccna2, cyclin E1 (Ccne1), cyclin B1
(Ccnb1), and Ccnb2 in HSCs from 15- to 17-month-old mice
(Figure 7C). In addition to Cdk6, Ccna2 and Ccnb1 were signifi-
cantly reduced in Bcl11a KO HSCs (Figure 5E).
One of the hallmarks of aging is increased occurrence of DNA
damage (Geiger et al., 2013; Rossi et al., 2008). Phosphorylation
of the histone H2A variant H2AX (gH2AX) is associated with DNA
damage and can be used as an early detection marker. Intracel-
lular staining against gH2AX inBcl11aWT and KOHSCs demon-
strated a significantly higher frequency of gH2AX in KO HSCs,
indicating increased DNA damage in the absence of Bcl11a (Fig-
ures 7D and 7E). As expected, we detected substantial gH2AX
signal in HSCs from an irradiated control (5 Gy) and comparable
levels of gH2AX between Bcl11afl/fl 3 Mx1-Cre (WT) and
Bcl11awt/wt 3 Mx1-Cre+ mice (Figures 7D and 7E; Figure S7A).
These findings are consistent with reports of increased DNA
damage in aged HSCs (Beerman et al., 2014).
Another mechanism proposed to underlie the cell-cycle
changes in aged HSCs is replication stress due to decreased
expression of mini-chromosome (Mcm) genes (Flach et al.,
2014). Six Mcm genes encode the hexameric DNA helicase
required for DNA replication (Flach et al., 2014). To determine
the age-associated changes in Mcm gene expression, HSCs
were purified from 2-month-old and 15- to 17-month-old mice.
Consistent with previous findings (Flach et al., 2014), the expres-
sion of all Mcm genes was significantly reduced in older mice
(Figure 7F). To examine whether loss of Bcl11a may have a
similar effect, we performed GSEA using a Mcm gene set (Flach
et al., 2014). The Mcm gene signature was downregulated in
Bcl11a KO HSCs (Figure 7G) and gene expression analysis of
Mcm genes showed a general decrease in Bcl11a-deficient
HSCs (Figure 7H). These results suggest that Bcl11a deficiency
may induce replication stress, similar to aged HSCs.
To confirm that Bcl11a-deficient HSCs have an aging pheno-
type, we assessed whether old WT HSCs associate with a
Bcl11a KO gene signature. We compared the gene expression
profiles in Bcl11a KO HSCs with published transcriptomic data-
sets from old (>22 months) and young (2–3 months) HSCs (Ko-
walczyk et al., 2015; Sun et al., 2014a). The gene expression
change in Bcl11a KO (versus WT) was positively correlated3190 Cell Reports 16, 3181–3194, September 20, 2016with the change in the aged (versus young) HSCs (Figure S7B).
More specifically, the upregulated genes in Bcl11a KO were
highly enriched in aged HSCs, whereas the downregulated
genes were enriched in young HSCs (Figure 7I), providing further
support for the overlapping phenotypes between Bcl11a-defi-
cient and aged HSCs.
Advancing age is often accompanied by the onset of anemia
(Geiger et al., 2013; Rossi et al., 2008). Thus, we measured he-
moglobin levels in Bcl11a WT and KO mice as an indicator of
anemia. As expected, there was no difference in hemoglobin
levels in 2-month-old Bcl11a WT and KO mice. Hemoglobin
levels in 10-month-old Bcl11a WT and KO mice were reduced
compared to levels in 2-month-old mice (Figure 7J). Hemoglobin
levels were further decreased in older Bcl11a-deficient mice
(p value = 0.005), whereas the level in Bcl11aWTmice was com-
parable to that in 20-month-old C57BL/6 mice (Figure 7J; Fig-
ure S7C). These findings demonstrate that the anemic condition
in older mice is exacerbated by loss of BCL11A.
Given the reported accrual of DNA damage with age (Geiger
et al., 2013; Rossi et al., 2008) and our observation that
BCL11A loss exacerbates age-associated anemia (Figure 7J;
Figure S7C), we hypothesized that phosphorylation of H2AX
should be further increased in older Bcl11a KO mice. Indeed,
gH2AX was significantly increased from the level in 2-month-
old to that in 8-month-old C57BL/6 HSCs, and the level of
gH2AX was further increased in Bcl11a KO HSCs (Figure 7K).
In summary, our findings strongly suggest that Bcl11a defi-
ciency results in a phenotypic resemblance to HSCs in the
aged hematopoietic system and that typical aging characteris-
tics are more pronounced in aged Bcl11a KO mice.
DISCUSSION
In the hematopoietic system, BCL11A is expressed in definitive
but not primitive hematopoiesis (Palis, 2014). In definitive hema-
topoiesis, BCL11A controls B lymphopoiesis by regulation of
apoptosis and cell survival through a p53-dependent pathway
(Yu et al., 2012). However, the role of BCL11A in other lineages,
especially in HSCs, remains elusive. Studies have implicated a
role of BCL11A in HSC self-renewal and lineage differentiation
(Kustikova et al., 2005; Tsang et al., 2015) that is distinct from
its role in B lymphopoiesis. Other studies have suggested that
BCL11A has oncogenic potential and can promote leukemia
development of both lymphoid and myeloid lineages (Alcalay
et al., 2003; Kustikova et al., 2005; Satterwhite et al., 2001; Yin
et al., 2009). The context-specific role of BCL11A illustrates the
importance of a comprehensive analysis of the in vivo function
of BCL11A in hematopoiesis as part of ongoing efforts to target
BCL11A for HbF induction, as well as to develop strategies to
generate bona fide definitive HSCs from ESCs or iPSCs.
In this study, we have systematically delineated the role
of BCL11A in definitive hematopoiesis, particularly in HSCs,
through hematopoietic-selective deletion of BCL11A. Our find-
ings indicate that Bcl11a is dispensable for HSCs in hemato-
poietic homeostasis, apart from B cell defects, as previously
reported (Liu et al., 2003; Yu et al., 2012). However, the func-
tion of Bcl11a-deficient HSCs is significantly impaired when
challenged. We also found that steady-state Bcl11a-deficient
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Figure 7. HSCs from Bcl11a-Deficient Mice Resemble the Phenotype of Aging HSCs
(A) GSEA of two aging gene signatures in Bcl11a WT and KO HSCs.
(B) Relative mRNA expression of Bcl11a and Cdk6 in sorted HSCs from 2-month-old and 15- to 17-month-old C57BL/6 mice. n = 4/group.
(C) Relative mRNA expression of cell-cycle genes in sorted HSCs from 2-month-old and 15- to 17-month-old C57BL/6 mice. n = 4/group.
(D) Representative FACS profiles of gH2AX staining in HSCs showing mean frequencies from (E).
(E) Frequency of gH2AX in HSCs from Bcl11aWT and KO mice 10 weeks post-p(I:C) and an irradiated control (5 Gy). n = 4 WT, 3 KO, and 1 irradiated control.
(F) Relative mRNA expression of Mcm genes in sorted HSCs from 2-month-old and 15- to 17-month-old C57BL/6 mice. n = 4/group.
(G) GSEA of a Mcm gene signature in Bcl11a WT and KO HSCs.
(H) Relative mRNA expression of Mcm genes in Bcl11a WT and KO HSCs, n = 6 WT and 7 KO.
(I) GSEA of upregulated and downregulated genes (R2-fold, p < 0.01) from Bcl11a KO mice in a dataset from old (>22 months old) and young (2–3 months old)
long-term HSCs acquired from Kowalczyk et al. (2015).
(J) Hemoglobin levels (in grams per deciliter) in 2-month-old (2-mo) and 10-month-old (10-mo)Bcl11aWT and KOmice. n = 8WT and 6 KO (2-mo) and 15WT and
8 KO (10-mo).
(K) Frequency of gH2AX in HSCs from 9-month-old (9-mo) Bcl11aWT and KO mice and 2- and 8-month-old (2- and 8-mo) C57BL/6 (B6) mice. n = 3 WT, 3 KO,
3 B6 (2-mo), and 2 B6 (8-mo).
In (A), (G), and (I), n = 3/genotype. Data represent mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S7.
Cell Reports 16, 3181–3194, September 20, 2016 3191
HSCs expressed quiescence gene signatures, consistent with
findings suggesting that steady-state hematopoiesis is mainly
sustained by short-term HSCs and other long-lived progenitors
(Busch et al., 2015; Sun et al., 2014b). Moreover, we demon-
strate that when challenged, Bcl11a KO HSCs exhibit cell-cycle
defects that result in increased cell-cycle entry, with a concom-
itant extension of cell-cycle transit. By measuring kinetics of cell
division in single HSCs, we showed that prolonged cell-cycle
transit is due to a delay in recruiting cells into the active cell cycle
and executing the first cell division. The cumulative effect of this
delay limits HSC divisions and ultimately leads to a net decrease
in cellular output. This likely also explains the increased cell-cy-
cle entry in Bcl11a KO HSCs as a compensatory effect. As a
result of the cell-cycle delay, Bcl11a-deficient HSCs are unable
to reconstitute blood lineages and self-renew to the same de-
gree as WT HSCs and are outcompeted in a transplantation
setting. Several cell-cycle regulators are decreased in Bcl11a-
deficient HSCs, including the G0/G1 regulator CDK6. CDK6
has been demonstrated to regulate quiescence exit in human
HSCs, and Cdk6-deficient HSCs are grossly normal until chal-
lenged (Laurenti et al., 2015; Scheicher et al., 2015). Thus, our
studies suggest that lower Cdk6 expression in Bcl11a-deficient
HSCs may be responsible for the delay in cell-cycle entry and
transit through G1.
Our findings differ from a previously published study, which
suggested that cell-cycle defects in Bcl11a-deficient HSCs
result in hyperproliferation and loss of quiescence (Tsang et al.,
2015). It is likely that the discrepancy is due to different experi-
mental protocols. A critical difference is the pan-cellular dele-
tion of Bcl11a through an estrogen-induced (CreERT) system
compared to the hematopoietic-selectiveMx1-Cre deletion sys-
tem used in this study. More importantly, administration of estro-
gen in mice has been shown to increase HSC divisions (Nakada
et al., 2014). Thus, it is likely that the observed HSC hyperprolif-
eration in the study by Tsang et al. (2015) is unrelated to Bcl11a
gene deletion. In this study, the use of the hematopoietic-selec-
tive, inducible Mx1-Cre allele avoids these confounding issues
and provides a better and more accurate assessment of the
HSC defect in Bcl11a-null mice.
Our findings have significant implications for ongoing efforts
to target BCL11A for the major b-hemoglobin disorders. Our re-
sults suggest that global targeting of BCL11A in stem and pro-
genitor cells, such as human CD34+ cells, is ill advised, because
the absence of BCL11A may adversely affect the function of
HSCs. Given BCL11A’s critical requirement in multiple hemato-
poietic lineages, therapeutic strategies that emphasize disrupt-
ing BCL11A selectively in erythroid cells while sparing its
expression in non-erythroid lineages need to be considered.
Furthermore, our studies illustrate that careful dissection of
HSC roles of therapeutic targets for gene therapy or gene
editing is required for a complete view of potential in vivo
consequences and may help in the design of better clinical
experiments.
HSCs continually replenish blood cells for a lifetime, and the
balance between proliferation and quiescence is carefully regu-
lated to ensure blood homeostasis. In the aging hematopoietic
system, there is a diminished capacity to adequately maintain
homeostasis despite increased numbers of phenotypic HSCs3192 Cell Reports 16, 3181–3194, September 20, 2016(Morrison et al., 1996; Rossi et al., 2008; Sudo et al., 2000). In
our study, loss of Bcl11a in the hematopoietic system exhibited
features highly resembling the aged hematopoietic system. The
overlapping of phenotypes observed between young Bcl11a-
deficient HSCs and aged WT HSCs is striking and extensive.
Although we were unable to detect a significant change in
Bcl11a mRNA expression in aged WT HSCs, several cell-cycle
regulators, including Cdk6, were decreased in both aged HSCs
and Bcl11a-deficient HSCs. Furthermore, aged HSCs have
been shown to exhibit delayed cell-cycle kinetics, despite being
recruited into the active cell cycle to a higher degree compared
to young HSCs (Flach et al., 2014). The attenuated cell cycle
in Bcl11a KO mice renders them unable to sustain hematopoie-
sis under conditions of stress and regeneration. Although the
phenotype is more severe and accelerated in Bcl11a KO mice
compared to aged mice, it suggests that common cell-cycle
pathways may be affected. Furthermore, the increase in HSC
numbers in the Bcl11a KO mouse is unable to compensate for
the functional defects, similar to the age-associated increase in
functionally impaired HSCs. Although the mechanism respon-
sible for this in the aging hematopoietic system remains elusive
(Geiger et al., 2013), cell-cycle changes and increased symmet-
rical divisions have been suggested. One of the hallmarks of ag-
ing is increased occurrence of gH2AX, which has been proposed
to be the earliest marker of DNA damage (Beerman et al., 2014;
Rossi et al., 2008) and a sign of replication stress (Flach et al.,
2014). The gH2AX level is markedly increased in Bcl11a-defi-
cient HSCs, which also correlated with decreased Mcm gene
expression, similar to the phenotype of replication stress
observed in the aged HSCs (Flach et al., 2014). Furthermore,
phenotypic features typically observed in the aging hemato-
poietic system, including increased gH2AX and decreased
hemoglobin levels, commonly associated with anemia, are
exacerbated in aged Bcl11a-deficient mice.
Despite progress in defining the characteristic features of
aged HSCs, the mechanisms underlying age-associated molec-
ular changes are largely unknown (Rossi et al., 2008). Here, we
present a potential connection between Bcl11a and the aging
hematopoietic system, mediated through the cell-cycle pro-
cess. The mechanisms by which BCL11A regulates the cell-
cycle mediator remain to be determined. It is plausible that
BCL11A acts indirectly through a mediator that regulates the
cell cycle, because we were unable to observe a significant
change in Bcl11a expression in aged mice. The gene expres-
sion of Bcl11a-deficient and aged HSCs was positively corre-
lated, indicating similarity in transcriptomic changes, although
comprehensive studies are needed to determine the extent of
the overlap and the specific genes and pathways involved.
Nevertheless, in the absence of Bcl11a, HSCs display self-
renewal and differentiation defects that render them unable to
sustain long-term hematopoiesis. These findings have revealed
a potential role of BCL11A in the aging hematopoietic system
and provide mechanistic insights into the regulation of definitive
HSCs by BCL11A. Hence, our study not only provides impor-
tant implications for the design of therapeutic strategies for
b-globin disorders but also benefits current efforts in character-
izing molecular mechanisms controlling aging and age-related
pathogenesis.
EXPERIMENTAL PROCEDURES
Experimental Animals
The Bcl11afl/fl mouse strain has been described previously (Ippolito et al.,
2014; Sankaran et al., 2009). Bcl11a deletion in Bcl11a 3 Mx1-Cre mice
was achieved by intraperitoneal administration of five doses of p(I:C)
(12.5 mg/g body weight) (InvivoGen). All experiments using adult mice were
performed with mouse strains backcrossed on a C57BL/6 background
(more than nine generations) unless stated otherwise. The Institutional Animal
Care and Use Committee at Boston Children’s Hospital approved all
experiments.
Flow Cytometry Experiments
For HSC analysis, BM cells were enriched for CD117 using MACS beads (Mil-
tenyi) before staining. In all flow cytometry analyses and purifications, Bcl11a
Het and KO mice were always gated positively for eYFP, in addition to the
indicated immunophenotypes, to analyze or isolate Bcl11a-deleted cells.
See Table S3 for a complete list of antibodies.
Transplantation Experiments
B6.SJL-Ptprca/BoyAiTac (CD45.1) (10–12 weeks old) mice were lethally irradi-
ated (two split doses of 500 cGy). Competitive transplantation was performed
by the intravenous injection of 200 donor HSCs (LSKCD48Flt3CD150+) and
200,000 whole BM cells (CD45.1).
Gene Expression Experiments
In real-time PCR experiments, relative expression was quantified using the
DDCt method and normalized to Gapdh. See Table S4 for primer sequences.
Global gene expression analysis by microarray was performed on the Affyme-
trix Mouse Gene 2.0 ST platform.
Bioinformatics Analyses
Affymetrix CEL files were normalized using robust multiarray average (RMA)
(Irizarry et al., 2003). Differentially expressed genes were detected with a
threshold of fold changeR 2 and adjusted p value% 0.01. Pathway enrich-
ment analyses were performed using GeneGo Metacore from Thomson
Reuters (v.6.24, build 67895) (https://portal.genego.com/). GSEA was
performed using GSEA software (http://software.broadinstitute.org/gsea/)
(Subramanian et al., 2005) with default parameters. Comparative analyses
with other published gene expression data derived on different platforms
were performed by comparison of differentially expressed genes (log2 fold
change).
Cell-Cycle and Cell Proliferation Experiments
Fixation and permeabilization were performed with the BD Cytofix/Cyto-
perm Kit (BD Biosciences) according to the manufacturer’s protocol, fol-
lowed by incubation with Ki-67 antibody and DAPI before flow cytometry
analysis.
Cell proliferation assays were performed by the administration of a single
intraperitoneal injection of BrdU. Fixation, permeabilization, and BrdU visuali-
zation were performed using the BDBrdU Flow Kit (BDBiosciences) according
to the manufacturer’s protocol.
Cell Division Analyses
Evaluation of cell division was performed by incubation with CellTrace Far Red
(Thermo Fisher Scientific) according to the manufacturer’s protocol, followed
by cell culturing for 6–7 days before fluorescence-activated cell sorting (FACS)
analysis (see Table S5 for growth factor conditions).
Evaluation of cell division kinetics was performed by plating single HSCs in
60-well plates (Nunc). The number of cells in the wells was scored 24 and 48 hr
after cell plating with an inverted microscope. Cell-counting experiments as-
sessing cellular expansion were performed using CountBright absolute count-
ing beads (Thermo Fisher Scientific).
Statistics
Statistical analysis was performed using the unpaired, two-tailed t test in
GraphPad Prism v.6.0h for Mac OS X.ACCESSION NUMBERS
The accession number for the microarray data reported in this paper is GEO:
GSE77207.
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